Profound Actions of an Agonist of Growth Hormone-Releasing Hormone on Angiogenic Therapy by Mesenchymal Stem Cells

Qunchao Ma, Xiangyang Xia, Quanwei Tao, Kai Lu, Jian Shen, Qiyuan Xu, Xinyang Hu, Yao Liang Tang, Norman L. Block, Keith A. Webster, Andrew V. Schally, Jian'An Wang, Hong Yu

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objective - The efficiency of cell therapy is limited by poor cell survival and engraftment. Here, we studied the effect of the growth hormone-releasing hormone agonist, JI-34, on mesenchymal stem cell (MSC) survival and angiogenic therapy in a mouse model of critical limb ischemia. Approach and Results - Mouse bone marrow-derived MSCs were incubated with or without 10-8 mol/L JI-34 for 24 hours. MSCs were then exposed to hypoxia and serum deprivation to detect the effect of preconditioning on cell apoptosis, migration, and tube formation. For in vivo tests, critical limb ischemia was induced by femoral artery ligation. After surgery, mice received 50 μL phosphate-buffered saline or with 1×106 MSCs or with 1×106 JI-34-reconditioned MSCs. Treatment of MSCs with JI-34 improved MSC viability and mobility and markedly enhanced their capability to promote endothelial tube formation in vitro. These effects were paralleled by an increased phosphorylation and nuclear translocation of signal transducer and activator of transcription 3. In vivo, JI-34 pretreatment enhanced the engraftment of MSCs into ischemic hindlimb muscles and augmented reperfusion and limb salvage compared with untreated MSCs. Significantly more vasculature and proliferating CD31+ and CD34+ cells were detected in ischemic muscles that received MSCs treated with JI-34. Conclusions - Our studies demonstrate a novel role for JI-34 to markedly improve therapeutic angiogenesis in hindlimb ischemia by increasing the viability and mobility of MSCs. These findings support additional studies to explore the full potential of growth hormone-releasing hormone agonists to augment cell therapy in the management of ischemia.

Original languageEnglish (US)
Pages (from-to)663-672
Number of pages10
JournalArteriosclerosis, thrombosis, and vascular biology
Volume36
Issue number4
DOIs
StatePublished - Apr 1 2016

Fingerprint

Growth Hormone-Releasing Hormone
Mesenchymal Stromal Cells
Ischemia
Cell Survival
Hindlimb
Cell- and Tissue-Based Therapy
Extremities
STAT3 Transcription Factor
Muscles
Limb Salvage
Femoral Artery
Therapeutics
Reperfusion
Cell Movement
Ligation
Bone Marrow
Phosphates
Phosphorylation
Apoptosis
Serum

Keywords

  • angiogenesis effects
  • growth hormone-releasing hormone
  • mesenchymal stromal cells

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Profound Actions of an Agonist of Growth Hormone-Releasing Hormone on Angiogenic Therapy by Mesenchymal Stem Cells. / Ma, Qunchao; Xia, Xiangyang; Tao, Quanwei; Lu, Kai; Shen, Jian; Xu, Qiyuan; Hu, Xinyang; Tang, Yao Liang; Block, Norman L.; Webster, Keith A.; Schally, Andrew V.; Wang, Jian'An; Yu, Hong.

In: Arteriosclerosis, thrombosis, and vascular biology, Vol. 36, No. 4, 01.04.2016, p. 663-672.

Research output: Contribution to journalArticle

Ma, Q, Xia, X, Tao, Q, Lu, K, Shen, J, Xu, Q, Hu, X, Tang, YL, Block, NL, Webster, KA, Schally, AV, Wang, JA & Yu, H 2016, 'Profound Actions of an Agonist of Growth Hormone-Releasing Hormone on Angiogenic Therapy by Mesenchymal Stem Cells', Arteriosclerosis, thrombosis, and vascular biology, vol. 36, no. 4, pp. 663-672. https://doi.org/10.1161/ATVBAHA.116.307126
Ma, Qunchao ; Xia, Xiangyang ; Tao, Quanwei ; Lu, Kai ; Shen, Jian ; Xu, Qiyuan ; Hu, Xinyang ; Tang, Yao Liang ; Block, Norman L. ; Webster, Keith A. ; Schally, Andrew V. ; Wang, Jian'An ; Yu, Hong. / Profound Actions of an Agonist of Growth Hormone-Releasing Hormone on Angiogenic Therapy by Mesenchymal Stem Cells. In: Arteriosclerosis, thrombosis, and vascular biology. 2016 ; Vol. 36, No. 4. pp. 663-672.
@article{213d53782dfa40d2a0b0c64ad410296a,
title = "Profound Actions of an Agonist of Growth Hormone-Releasing Hormone on Angiogenic Therapy by Mesenchymal Stem Cells",
abstract = "Objective - The efficiency of cell therapy is limited by poor cell survival and engraftment. Here, we studied the effect of the growth hormone-releasing hormone agonist, JI-34, on mesenchymal stem cell (MSC) survival and angiogenic therapy in a mouse model of critical limb ischemia. Approach and Results - Mouse bone marrow-derived MSCs were incubated with or without 10-8 mol/L JI-34 for 24 hours. MSCs were then exposed to hypoxia and serum deprivation to detect the effect of preconditioning on cell apoptosis, migration, and tube formation. For in vivo tests, critical limb ischemia was induced by femoral artery ligation. After surgery, mice received 50 μL phosphate-buffered saline or with 1×106 MSCs or with 1×106 JI-34-reconditioned MSCs. Treatment of MSCs with JI-34 improved MSC viability and mobility and markedly enhanced their capability to promote endothelial tube formation in vitro. These effects were paralleled by an increased phosphorylation and nuclear translocation of signal transducer and activator of transcription 3. In vivo, JI-34 pretreatment enhanced the engraftment of MSCs into ischemic hindlimb muscles and augmented reperfusion and limb salvage compared with untreated MSCs. Significantly more vasculature and proliferating CD31+ and CD34+ cells were detected in ischemic muscles that received MSCs treated with JI-34. Conclusions - Our studies demonstrate a novel role for JI-34 to markedly improve therapeutic angiogenesis in hindlimb ischemia by increasing the viability and mobility of MSCs. These findings support additional studies to explore the full potential of growth hormone-releasing hormone agonists to augment cell therapy in the management of ischemia.",
keywords = "angiogenesis effects, growth hormone-releasing hormone, mesenchymal stromal cells",
author = "Qunchao Ma and Xiangyang Xia and Quanwei Tao and Kai Lu and Jian Shen and Qiyuan Xu and Xinyang Hu and Tang, {Yao Liang} and Block, {Norman L.} and Webster, {Keith A.} and Schally, {Andrew V.} and Jian'An Wang and Hong Yu",
year = "2016",
month = "4",
day = "1",
doi = "10.1161/ATVBAHA.116.307126",
language = "English (US)",
volume = "36",
pages = "663--672",
journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",
issn = "1079-5642",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Profound Actions of an Agonist of Growth Hormone-Releasing Hormone on Angiogenic Therapy by Mesenchymal Stem Cells

AU - Ma, Qunchao

AU - Xia, Xiangyang

AU - Tao, Quanwei

AU - Lu, Kai

AU - Shen, Jian

AU - Xu, Qiyuan

AU - Hu, Xinyang

AU - Tang, Yao Liang

AU - Block, Norman L.

AU - Webster, Keith A.

AU - Schally, Andrew V.

AU - Wang, Jian'An

AU - Yu, Hong

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Objective - The efficiency of cell therapy is limited by poor cell survival and engraftment. Here, we studied the effect of the growth hormone-releasing hormone agonist, JI-34, on mesenchymal stem cell (MSC) survival and angiogenic therapy in a mouse model of critical limb ischemia. Approach and Results - Mouse bone marrow-derived MSCs were incubated with or without 10-8 mol/L JI-34 for 24 hours. MSCs were then exposed to hypoxia and serum deprivation to detect the effect of preconditioning on cell apoptosis, migration, and tube formation. For in vivo tests, critical limb ischemia was induced by femoral artery ligation. After surgery, mice received 50 μL phosphate-buffered saline or with 1×106 MSCs or with 1×106 JI-34-reconditioned MSCs. Treatment of MSCs with JI-34 improved MSC viability and mobility and markedly enhanced their capability to promote endothelial tube formation in vitro. These effects were paralleled by an increased phosphorylation and nuclear translocation of signal transducer and activator of transcription 3. In vivo, JI-34 pretreatment enhanced the engraftment of MSCs into ischemic hindlimb muscles and augmented reperfusion and limb salvage compared with untreated MSCs. Significantly more vasculature and proliferating CD31+ and CD34+ cells were detected in ischemic muscles that received MSCs treated with JI-34. Conclusions - Our studies demonstrate a novel role for JI-34 to markedly improve therapeutic angiogenesis in hindlimb ischemia by increasing the viability and mobility of MSCs. These findings support additional studies to explore the full potential of growth hormone-releasing hormone agonists to augment cell therapy in the management of ischemia.

AB - Objective - The efficiency of cell therapy is limited by poor cell survival and engraftment. Here, we studied the effect of the growth hormone-releasing hormone agonist, JI-34, on mesenchymal stem cell (MSC) survival and angiogenic therapy in a mouse model of critical limb ischemia. Approach and Results - Mouse bone marrow-derived MSCs were incubated with or without 10-8 mol/L JI-34 for 24 hours. MSCs were then exposed to hypoxia and serum deprivation to detect the effect of preconditioning on cell apoptosis, migration, and tube formation. For in vivo tests, critical limb ischemia was induced by femoral artery ligation. After surgery, mice received 50 μL phosphate-buffered saline or with 1×106 MSCs or with 1×106 JI-34-reconditioned MSCs. Treatment of MSCs with JI-34 improved MSC viability and mobility and markedly enhanced their capability to promote endothelial tube formation in vitro. These effects were paralleled by an increased phosphorylation and nuclear translocation of signal transducer and activator of transcription 3. In vivo, JI-34 pretreatment enhanced the engraftment of MSCs into ischemic hindlimb muscles and augmented reperfusion and limb salvage compared with untreated MSCs. Significantly more vasculature and proliferating CD31+ and CD34+ cells were detected in ischemic muscles that received MSCs treated with JI-34. Conclusions - Our studies demonstrate a novel role for JI-34 to markedly improve therapeutic angiogenesis in hindlimb ischemia by increasing the viability and mobility of MSCs. These findings support additional studies to explore the full potential of growth hormone-releasing hormone agonists to augment cell therapy in the management of ischemia.

KW - angiogenesis effects

KW - growth hormone-releasing hormone

KW - mesenchymal stromal cells

UR - http://www.scopus.com/inward/record.url?scp=84957927811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957927811&partnerID=8YFLogxK

U2 - 10.1161/ATVBAHA.116.307126

DO - 10.1161/ATVBAHA.116.307126

M3 - Article

C2 - 26868211

AN - SCOPUS:84957927811

VL - 36

SP - 663

EP - 672

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

SN - 1079-5642

IS - 4

ER -